TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14620619
Drug: 10-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day standard triple therapy (group C)
Study: 7036283
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg poly A‐poly U i.v. once a week for 6 weeks
Study: 29203151
Drug: ADV6209 (2mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV6209 (2mg/ml oral solution of midazolam containing cyclodextrin)
Study: 20415574
Drug: Delayed ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed ART (after 10 weeks of treatment with fluconazole alone)
Study: 12351537
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) patch administered the day before embryo transfer and continued until pregnancy test results or menstruation
Study: 7781399
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and RT
Study: 7781399
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality of RT and chemotherapy
Study: 11850096
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment for 4 weeks
Study: 6108779
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg + Morphine 5 mg
Study: 6108779
Drug: Lorazepam 4
Normalized name: lorazepam 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4 mg + Morphine 5 mg
Study: 6108779
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg and 4 mg
Study: 6653648
Drug: Diazoxide 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide 150 mg
Study: 6653648
Drug: Labetalol 50
Normalized name: labetalol 500 mg/500 mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 50 mg
Study: 30915467
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS) provided daily during pregnancy and first 6 months postpartum, and to infants from age 6 to 18 months.
Study: 30915467
Drug: Non-LNS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-LNS group received daily iron and folic acid or multiple micronutrients during pregnancy and first 6 months postpartum, with no infant supplementation.
Study: 27085586
Drug: PF‐06260414 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06260414 (1 to 400 mg for SAD, 3 to 100 mg BID for MAD, 60 mg once-daily, 30 mg BID for Japanese cohort)
Study: 27085586
Drug: PF‐06260414 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06260414 (100 mg BID)
Study: 18612863
Drug: Clinician-assisted computerized
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-assisted computerized cognitive behavioural treatment programme
Study: 16038711
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy (control group)
Study: 16038711
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral anticoagulants (control group)
Study: 31244487
Drug: TheraSling therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TheraSling therapy (TST) combined with neuromuscular facilitation technique
Study: 25072405
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy administered over the telephone (CBT-T)
Study: 25072405
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy administered in-person (CBT-IP)
Study: 16499515
Drug: Buprenorphine depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine depot injection (58 mg)
Study: 12910861
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fraxiparin)
Study: 10884451
Drug: rTPA (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTPA (0.9 mg/kg IV)
Study: 9333327
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (1-3 μg x kg-1 x min-1)
Study: 9333327
Drug: Routine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine administration of low-dose dopamine
Study: 8480823
Drug: Multicomponent behavioral
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent behavioral treatment
Study: 8480823
Drug: Drug abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug abuse counseling
Study: 28334979
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication reviews (CMR)
Study: 18584240
Drug: Low-dose TACE
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TACE (2 mg mitomycin C, 10 mg epirubicin, 100 mg carboplatin)
Study: 18584240
Drug: High-dose TACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TACE (10 mg mitomycin C, 40 mg epirubicin, 300 mg carboplatin)
Study: 14560892
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for early-stage endometriosis
Study: 14560892
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for moderate and severe endometriosis
Study: 14560892
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment inducing an anovulatory state
Study: 10964269
Drug: Indoor residual
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor residual spraying with alphacypermethrin (Fendona) at 25 mg/m2
Study: 10964269
Drug: Indoor residual
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor residual spraying with suspension concentrate (SC) formulation
Study: 8829929
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 1 mg kg‐1 lignocaine 2% to the medial part of the eye after induction of anaesthesia (Group II)
Study: 8829929
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of lignocaine after a 5 min interval (Group III)
Study: 1392493
Drug: Rose Shu‐Xin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rose Shu‐Xin oral liquid
Study: 1392493
Drug: Salvia miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia miltiorrhiza tablet
Study: 2414590
Drug: Verapamil 160
Normalized name: verapamil 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 160 mg
Study: 2414590
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (general)
Study: 27346728
Drug: Brivaracetam 10
Normalized name: brivaracetam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 10 mg tablet
Study: 27346728
Drug: Brivaracetam 75
Normalized name: brivaracetam 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 75 mg tablet
Study: 27346728
Drug: Brivaracetam 100
Normalized name: brivaracetam 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 100 mg tablet
Study: 27346728
Drug: Brivaracetam 100
Normalized name: brivaracetam 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 100 mg intravenous bolus
Study: 27346728
Drug: Brivaracetam 50
Normalized name: brivaracetam 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 50 mg tablet
Study: 25891548
Drug: Low-dose PDA-001
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PDA-001 (150×10(6) cells)
Study: 25891548
Drug: High-dose PDA-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PDA-001 (600×10(6) cells)
Study: 20727735
Drug: ECC+P (Epirubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECC+P (Epirubicin, Cisplatin, Capecitabine + Pravastatin 40 mg once daily)
Study: 31734798
Drug: Medication Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Management Service (MMS)
Study: 26394882
Drug: tiotropium (18 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium (18 μg once daily) + budesonide/formoterol (160/4.5 μg 2 inhalations twice daily)
Study: 26394882
Drug: tiotropium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium alone (18 μg once daily)
Study: 18485132
Drug: Torasemide prolonged
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide prolonged release (PR) 5 mg/day (uptitration to 10 mg/day if no response at 4 or 8 weeks)
Study: 18485132
Drug: Torasemide immediate
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide immediate release (IR) 5 mg/day (uptitration to 10 mg/day if no response at 4 or 8 weeks)
Study: 16181001
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg budesonide inhaled from a Respimat Soft Mist Inhaler (Respimat SMI)
Study: 16181001
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg budesonide inhaled from a Turbuhaler dry powder inhaler (Turbuhaler DPI) with fast inhaled flow rate
Study: 16181001
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg budesonide inhaled from a Turbuhaler dry powder inhaler (Turbuhaler DPI) with slow inhaled flow rate
Study: 16181001
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg beclomethasone dipropionate inhaled from a pressurized metered dose inhaler (Becloforte pMDI)
Study: 12774138
Drug: Topical nitroglycerine
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerine ointment (NGO) applied 10 minutes prior to heelstick
Study: 12774138
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied 10 minutes prior to heelstick
Study: 12774138
Drug: Topical nitroglycerine
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerine ointment (NGO)
Study: 7982419
Drug: Controlled-release, prostacyclin-sparing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release, prostacyclin-sparing aspirin 75 mg daily plus anticoagulation (intravenous heparin followed by warfarin)
Study: 7982419
Drug: Conventional aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional aspirin 75 mg daily plus anticoagulation (intravenous heparin followed by warfarin)
Study: 3338726
Drug: Experimental residential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental residential treatment program
Study: 5762643
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated rubella vaccines
Study: 23981507
Drug: Web-based coaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based coaching program with education, motivation, exercise guidance, daily SMS reminders, weekly feedback, and active monitoring by general practitioners.
Study: 21346383
Drug: Preoperative CRT
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative CRT (45 Gy with chemotherapy)
Study: 21346383
Drug: Postoperative CRT
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative CRT (45‐51 Gy with chemotherapy)
Study: 16597076
Drug: Beclate and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclate and Qvar at higher doses
Study: 12569265
Drug: HCT (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCT (25 mg once daily for 9 days)
Study: 12569265
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + LOS (50 mg twice daily for 9 days)
Study: 11050587
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel plus UVB phototherapy
Study: 11050587
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel plus UVB phototherapy
Study: 27252432
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 (6 mL)
Study: 27252432
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (1 mL of 40-mg + 5 mL of 1% lidocaine with epinephrine)
Study: 25708913
Drug: everolimus targeting
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus targeting 3-8 ng/ml with reduced-exposure cyclosporine (CsA)
Study: 25708913
Drug: everolimus targeting
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus targeting 6-12 ng/ml with reduced-exposure cyclosporine (CsA)
Study: 23739514
Drug: Levetiracetam (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (60 mg/kg/day for one year)
Study: 20687400
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg/day) administered for 8 to 12 weeks before and during ovarian stimulation
Study: 9839106
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg/day)
Study: 8656661
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg as monotherapy
Study: 8656661
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg plus hydrochlorothiazide (HCTZ 12.5 mg)
Study: 8656661
Drug: Hydrochlorothiazide (HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ 12.5 mg) alone
Study: 6127964
Drug: Oral low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral low-dose combination of theophylline (280 mg) and terbutaline (2.5 mg)
Study: 6127964
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral dose of terbutaline (5 mg)
Study: 6127964
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of beta 2-adrenostimulant (1.25 mg terbutaline sulphate)
Study: 19747435
Drug: Oral pinaverium
Normalized name: pinaverium
DrugBank: Pinaverium (DB09090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pinaverium (Control)
Study: 17059993
Drug: beta-blocker, metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker, metoprolol
Study: 17059993
Drug: angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: angiotensin-converting enzyme inhibitor, ramipril
Study: 17059993
Drug: dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: dihydropyridine calcium channel blocker, amlodipine
Study: 17059993
Drug: usual-blood pressure
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual-blood pressure treatment goal
Study: 17059993
Drug: low-blood pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-blood pressure treatment goal
Study: 12969086
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of non-steroidal anti-inflammatory drugs
Study: 11482713
Drug: Dobutamine stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine stress (start dose 5 microg/kg/min to maximum dose 15 microg/kg/min)
Study: 1312002
Drug: Quinapril 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 2.5 mg
Study: 1312002
Drug: Quinapril 5
Normalized name: quinapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 5 mg
Study: 1312002
Drug: Quinapril 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 0.5 mg
Study: 1312002
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of Quinapril
Study: 1312002
Drug: Doses above
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses above 2.5 mg of Quinapril
Study: 2858217
Drug: Propoxyphene (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene (65 mg every 6 h) with Alprazolam (1.0 mg orally)
Study: 2858217
Drug: Propoxyphene (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene (65 mg every 6 h) with Diazepam (10 mg i.v.)
Study: 2858217
Drug: Propoxyphene (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene (65 mg every 6 h) with Lorazepam (2 mg i.v.)
Study: 31239321
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) of single-agent chemotherapy
Study: 23684618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, Group E)
Study: 19685375
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFAs) - 2 capsules of Omacor twice daily
Study: 19685375
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 2 capsules of placebo
Study: 11177210
Drug: High-flavonol (HF)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavonol (HF) diet including one 150 g onion cake (89.7 mg quercetin) and one 300 ml cup of black tea (1.4 mg quercetin) daily for 14 days
Study: 9091008
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia (2 ml of 2% mepivacaine)
Study: 3532315
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment with inhaled salbutamol (400 micrograms qds)
Study: 3532315
Drug: Irregular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular treatment with inhaled salbutamol (400 micrograms prn)
Study: 24832687
Drug: Structured conversation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured conversation about patient goals and preferences for medical treatment
Study: 22324939
Drug: Calcium montmorillonite
Normalized name: Montmorillonite
DrugBank: Montmorillonite (DB13654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium montmorillonite (NovaSil, NS) at a dosage of 3 g day⁻¹ for 3 months
Study: 22324939
Drug: Calcium montmorillonite
Normalized name: Montmorillonite
DrugBank: Montmorillonite (DB13654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium montmorillonite (NovaSil, NS) at a dosage of 1.5 g day⁻¹ for 3 months
Study: 20669673
Drug: Tongxinluo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo Capsule (TXLC)
Study: 16701189
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (Group I)
Study: 16701189
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg intravenous magnesium (Group II)
Study: 16701189
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg magnesium added to local anesthetic (Group III)
Study: 16701189
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg magnesium added to local anesthetic (Group IV)
Study: 4051211
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (1.4 mg)
Study: 29788982
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave lithotripsy (ESWL) as the first treatment option
Study: 29788982
Drug: Ureteroscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ureteroscopic treatment
Study: 23194481
Drug: Otamixaban (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (0.08 mg/kg intravenous bolus at randomization then 0.100 or 0.140 mg/kg per hour intravenous infusion)
Study: 18609695
Drug: Radiotherapy (irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (irradiation dose of 20 Gy/10 f/12 d, 40 Gy/20 f/24 d, and 60 Gy/30 f/36 d)
Study: 16117982
Drug: Prescript-Assist (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescript-Assist (500 mg capsule BID)
Study: 12049852
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg/d) during 6 weeks after delivery
Study: 8648369
Drug: Epirubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 40 mg/m2
Study: 8648369
Drug: Epirubicin 135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 135 mg/m2
Study: 6751833
Drug: 750 ml
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 ml spacer
Study: 24337079
Drug: BMS-820836 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-820836 0.5 mg
Study: 24337079
Drug: BMS-820836 3
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-820836 3 mg
Study: 24337079
Drug: BMS-820836 (0.025-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-820836 (0.025-3 mg)
Study: 22672253
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to the GP requesting treatment according to NICE's 'stepped care' recommendations
Study: 8593013
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg orally every 12 h for five doses
Study: 8593013
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg orally every 24 h for three doses
Study: 2503289
Drug: Daily bicycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bicycle exercise at 75 W for 1 hour during IVF